Global Hemophilia Treatment Market Set for Remarkable Growth, Forecasted to Reach US$21.3 Billion by 2027

Global Hemophilia Treatment Market Set for Remarkable Growth, Forecasted to Reach US$21.3 Billion by 2027

The global hemophilia treatment market, which achieved a substantial revenue of US$14.8 billion in 2021, is poised for significant expansion in the coming years. According to the latest findings from Fairfield Market Research, the market is expected to experience robust growth at a CAGR of 5.2% during the forecast period of 2022-2027, ultimately reaching a market value of US$21.3 billion.

Rising Demand Driven by Increasing Prevalence of Blood Clotting and Bleeding Disorders

Hemophilia, a rare X-linked recessive bleeding disorder characterized by improper blood clotting due to a deficiency or absence of clotting factors, has been on the rise globally. This condition, categorized as a rare/orphan disease, affects a relatively small population worldwide. There are three primary types of hemophilia: hemophilia A, hemophilia B, and acquired hemophilia, with approximately 70% of cases being inherited. The perpetual increase in the prevalence of blood clotting and bleeding-related diseases, combined with an uptick in testing, has expanded the target population for hemophilia treatment.

Introduction of Innovative Therapeutics as a Primary Growth Driver

The introduction of novel therapeutic approaches, including extended half-life factor concentrates, biphasic antibodies (FVIII mimetics), and gene therapy/editing, has significantly improved the treatment of individuals with hemophilia. Extended half-life factor concentrates have not only reduced the burden of care for patients but have also allowed for higher factor trough levels during regular replacement therapy. Despite the progress, challenges persist, such as the need for intravenous infusion in factor concentrate-based treatments and the risk of allo-antibody formation in some patients. Notably, Hemlibra (emicizumab) is gaining market share as a more convenient and effective alternative to older hemophilia treatments.

Lucrative Growth Opportunities with Safe and Effective Gene Therapy Solutions

Promising developments in gene therapy offer potential breakthroughs in hemophilia treatment. Several hemophilia gene therapies are advancing to late-stage clinical trials, with a focus on resolving the unique challenges associated with hemophilia A and B. The use of molecular genetic information has shown promise in delivering human hemophilia gene therapy, particularly for hemophilia B. The prospect of personalized medication is expected to contribute significantly to the growth of the hemophilia treatment market.

Shift Towards Asia Pacific for Phenomenal Growth

While developed countries in North America and Europe currently dominate the market, the Asia Pacific region is expected to exhibit the highest growth rate during the forecast period, driven by the availability of advanced treatments at more affordable prices and a continuously rising patient population.

Barriers to Growth: High Costs and Reluctance in Adopting Advanced Therapies

Despite the positive outlook, challenges persist in the hemophilia treatment market. Limited awareness and the lack of cost-effective treatment options in developing economies continue to hinder growth. Additionally, the safety and efficacy of newly launched treatments may pose obstacles. Reluctance among patients to switch from established treatments, coupled with the high cost of novel therapies and limited government rebates, restricts the adoption of advanced hemophilia care.

Key Market Players Focusing on R&D and Global Expansion

Leading players in the global hemophilia treatment market, including Bayer AG, BioMarin Pharmaceuticals, Inc., F. Hoffman La Roche Ltd., Grifols S.A., Sanofi, Takeda Pharmaceuticals Company Ltd., CSL Behring, Medexus Pharmaceuticals Inc., Novo Nordisk, Octapharma AG, and Pfizer Inc., are prioritizing research and development efforts and expanding their geographic reach to strengthen their global market positioning.

The global hemophilia treatment market is on a trajectory of substantial growth, driven by innovative therapies and expanding patient populations. As advancements in treatment options continue, the market is poised to provide better outcomes for individuals living with hemophilia.

Global Hemophilia Treatment Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2027 – [ 2023 UPDATE Available – Forecast 2023-2030*] (By Disease, Product, Patient, Treatment, Therapy, Drug Class, Route of Administration, End Use, By Geography, Leading Companies) https://www.fairfieldmarketresearch.com/report/hemophilia-treatment-market

Our Trending Reports:

Glaucoma Treatment Market

https://www.fairfieldmarketresearch.com/report/glaucoma-treatment-market

Infertility Treatment Market

https://www.fairfieldmarketresearch.com/report/infertility-treatment-market

Alopecia Treatment Market

https://www.fairfieldmarketresearch.com/report/alopecia-treatment-market

About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.

Contact

Fairfield Market Research

London, UK

UK +44 (0)20 30025888

USA (Toll-free) +1 (844) 3829746

Web: https://www.fairfieldmarketresearch.com/

Email: sales@fairfieldmarketresearch.com

LinkedIn | Twitter

This press release first seen on Brilad

comtex tracking

COMTEX_440910051/2840/2023-09-25T13:12:24

Post Disclaimer

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No DigiShor journalist was involved in the writing and production of this article.